


Please replace the paragraph at page 18, lines 19-31, with the following rewritten paragraph:

A2 The 1,4,7,10-tetraazacyclododecane-N,N', N'', N'''-tetra acetic acid (DOTA)-biotin conjugate (DOTA-LC-biotin) depicted below has been reported to have desirable in vivo biodistribution and is cleared primarily by renal excretion.



DOTA may also be conjugated to other ligands or to anti-ligands in the practice of the present invention.

In the Claims:

Please cancel claims 1-20 without prejudice.

Please add new claims 21-36 to read as follows:

A3 21. (New) A charge-modified proteinaceous compound wherein the proteinaceous compound that is charge modified is a targeting moiety, a conjugate containing said targeting moiety, or a diagnostic or therapeutic active agent.

22. (New) The charge-modified proteinaceous compound of claim 21 wherein said compound exhibits a serum half-life that is at least 10% greater than the serum half-life of the unmodified protein.

23. (New) The charge-modified proteinaceous compound of claim 21 wherein said compound exhibits a serum half-life that is at least 20% greater than the serum half-life of the unmodified protein.